Hemcheck Sweden AB has signed an exclusive distribution agreement with HKO Medical Systems d.o.o (“HKO”), a leading distributor of medical equipment in Croatia. The agreement will be in force from March and valid until the end of April 2023, concerning the Croatian market. HKO has committed to an initial purchase order of readers and one-time tests for a value of 7,000 EUR.
– HKO is a well-established and leading distributor in Croatia. They represent well known global companies such as Siemens Healthineers and Greiner Bio-One and we believe they are a very good fit for us. We very much look forward to this collaboration, says Joen Averstad, CEO of Hemcheck.
– We are very happy and enthusiastic about this distributor agreement with Hemcheck. They have a very interesting and innovative solution, and we are already planning several product tests in our market. We very much look forward to the collaboration, says Ana Martinovic Kurjak, Managing Director of HKO.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
About HKO Medical Systems d.o.o.
HKO is a leading distributor in Croatia and sells medical equipment for ultrasound, radiology, endoscopy and laboratory diagnostics, as well as equipment for operating rooms. HKO serves public institutions, hospitals, health centers, as well as private hospitals and clinics. It is a partner in the local market to global companies such as Siemens Healthineers, Greiner Bio-One, and Sony Healthcare.
Read more at http://www.hko.hr/
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.
This information is such information that Hemcheck is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on March 31, 2021 at 23.10